LY353381 in Preventing Breast Cancer in Women With Hyperplasia

DISEASE CHARACTERISTICS: * Current random fine needle breast aspiration (FNA) evidence of 1 of the following: * Hyperplasia with atypia * Hyperplasia without atypia but with a 10-year modified Gail risk of at least 4% * Hyperplasia without atypia but with a BRCAPRO risk of at least 25% * Hyperplasia without atypia but with a known mutation in BRCA1 or BRCA2 * Hyperplasia without atypia but with a history of contralateral ductal carcinoma in situ or invasive breast cancer * FNA must have been taken during days 1-14 of the menstrual cycle for premenopausal women * Classified as ACR class I-III on mammogram with stepwedge within past 6 months If intact uterus and/or ovaries, must have color doppler transvaginal pelvic sonogram within past 6 months showing endometrial thickening no greater than 13 mm premenopausal or no greater than 8 mm postmenopausal * No ovarian cysts felt to be possibly or probably non-physiologic that have not resolved to gynecologist's satisfaction on repeat sonogram * Must agree to have or have had genetic counseling and genetic testing performed for BRCA1 and BRCA2 * No active cancer (e.g., detectable disease) * Hormone receptor status: * Not specified PATIENT CHARACTERISTICS: Age: * 18 and over Sex: * Female Menopausal status: * Any Performance status: * Not specified Life expectancy: * At least 12 months Hematopoietic: * Hemoglobin greater than 10 g/dL * Granulocyte count greater than 1,000/mm\^3 * No deficiencies in protein C, protein S, or antithrombin III * No activated protein C resistance Hepatic: * Albumin greater than 3.0 g/dL * Bilirubin less than 1.5 mg/dL * AST less than 100 U/L * Alkaline phosphatase less than 200 U/L Renal: * Creatinine less than 1.5 mg/dL Cardiovascular: * No history of deep venous thrombosis not related to trauma or pregnancy * No severe coronary artery disease * No history of prior stroke Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after study * No other active cancer * No retinal vein thrombosis * No concurrent severe poorly controlled migraine * No factor V Leiden mutation carrier PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 12 months since prior immunotherapy Chemotherapy: * At least 3 months between completion of prior KUMC phase II difluoromethylornithine (DFMO) study and baseline aspiration * At least 12 months since prior chemotherapy Endocrine therapy: * Must not have started or stopped hormone replacement therapy or oral contraceptives within 6 months of baseline aspiration * Must continue all hormone replacement therapy and/or oral contraceptives that were being taken at time of baseline aspiration * At least 12 months since prior tamoxifen, raloxifene, or other antihormonal therapy Radiotherapy: * At least 3 months since prior radiotherapy Surgery: * At least 6 months between prior oophorectomy and baseline aspiration Other: * At least 2 weeks since the start of other new medication that would be ingested for 1 or more months